Medizinonline Medizinonline
  • News
    • News
    • Market & Medicine
  • Patients
    • Disease patterns
    • Diagnostics
    • Therapy
  • Partner Content
    • Dermatology
      • Atopic dermatitis and psoriasis news
      • Dermatology News
    • Diabetes
      • Dia-Month Club – Type 2 Diabetes
      • Diabetes in Motion
      • Diabetes Podcasts
    • Gastroenterology
      • IBD matters
      • Ozanimod: ulcerative colitis
      • Reflux Update
    • Immunology
      • Primary immunodeficiency – exchange of experience
    • Vaccinate
      • Herpes zoster
    • Infektiologie
    • Neurology
      • EXPERT ULTRASONIC: Introduction to ultrasound-guided injection
      • MS News
      • MS Therapy in Transition
    • Oncology
      • Swiss Oncology in motion
    • Orthopedics
      • Osteoporosis in motion
    • Phytotherapie
    • Practice Management
      • Aargau Cantonal Bank
      • Claraspital
    • Psychiatry
      • Geriatric Psychiatry
    • Rheumatology
  • Departments
    • Allergology and clinical immunology
    • General Internal Medicine
    • Anesthesiology
    • Angiology
    • Surgery
    • Dermatology and venereology
    • Endocrinology and Diabetology
    • Nutrition
    • Gastroenterology and Hepatology
    • Genetics
    • Geriatrics
    • Gynecology
    • Hematology
    • Infectiology
    • Cardiology
    • Nephrology
    • Neurology
    • Emergency and intensive care medicine
    • Nuclear Medicine
    • Oncology
    • Ophthalmology
    • ORL
    • Orthopedics
    • Pediatrics
    • Pharmacology and toxicology
    • Pharmaceutical medicine
    • Phlebology
    • Physical medicine and rehabilitation
    • Pneumology
    • Prevention and health care
    • Psychiatry and psychotherapy
    • Radiology
    • Forensic Medicine
    • Rheumatology
    • Sports Medicine
    • Traumatology and trauma surgery
    • Tropical and travel medicine
    • Urology
    • Dentistry
  • CME & Congresses
    • CME continuing education
    • Congress Reports
    • Congress calendar
  • Practice
    • Noctimed
    • Practice Management
    • Jobs
    • Interviews
  • Log In
  • Register
  • My account
  • Contact
  • English
    • Deutsch
    • Français
    • Italiano
    • Português
    • Español
  • Publications
  • Contact
  • Deutsch
  • English
  • Français
  • Italiano
  • Português
  • Español
Subscribe
Medizinonline Medizinonline
Medizinonline Medizinonline
  • News
    • News
    • Market & Medicine
  • Patienten
    • Krankheitsbilder
    • Diagnostik
    • Therapie
  • Partner Content
    • Dermatology
      • Atopic dermatitis and psoriasis news
      • Dermatology News
    • Diabetes
      • Dia-Month Club – Type 2 Diabetes
      • Diabetes in Motion
      • Diabetes Podcasts
    • Gastroenterology
      • IBD matters
      • Ozanimod: ulcerative colitis
      • Reflux Update
    • Immunology
      • Primary immunodeficiency – exchange of experience
    • Vaccinate
      • Herpes zoster
    • Infektiologie
    • Neurology
      • EXPERT ULTRASONIC: Introduction to ultrasound-guided injection
      • MS News
      • MS Therapy in Transition
    • Oncology
      • Swiss Oncology in motion
    • Orthopedics
      • Osteoporosis in motion
    • Phytotherapie
    • Practice Management
      • Aargau Cantonal Bank
      • Claraspital
    • Psychiatry
      • Geriatric Psychiatry
    • Rheumatology
  • Departments
    • Fachbereiche 1-13
      • Allergology and clinical immunology
      • General Internal Medicine
      • Anesthesiology
      • Angiology
      • Surgery
      • Dermatology and venereology
      • Endocrinology and Diabetology
      • Nutrition
      • Gastroenterology and Hepatology
      • Genetics
      • Geriatrics
      • Gynecology
      • Hematology
    • Fachbereiche 14-26
      • Infectiology
      • Cardiology
      • Nephrology
      • Neurology
      • Emergency and intensive care medicine
      • Nuclear Medicine
      • Oncology
      • Ophthalmology
      • ORL
      • Orthopedics
      • Pediatrics
      • Pharmacology and toxicology
      • Pharmaceutical medicine
    • Fachbereiche 26-38
      • Phlebology
      • Physical medicine and rehabilitation
      • Phytotherapy
      • Pneumology
      • Prevention and health care
      • Psychiatry and psychotherapy
      • Radiology
      • Forensic Medicine
      • Rheumatology
      • Sports Medicine
      • Traumatology and trauma surgery
      • Tropical and travel medicine
      • Urology
      • Dentistry
  • CME & Congresses
    • CME continuing education
    • Congress Reports
    • Congress calendar
  • Practice
    • Noctimed
    • Practice Management
    • Jobs
    • Interviews
Login

Sie haben noch keinen Account? Registrieren

  • An update

Cochrane analysis compares eleven substances in MS

    • Neurology
    • RX
    • Studies
  • 2 minute read

The aim of a recent meta-analysis by the Cochrane Collaboration was to compare eleven agents used in relapsing-remitting multiple sclerosis (RRMS) in terms of reduction in relapse rates, disability progression, and benefit-risk ratio. Differences in efficacy were sometimes shown: subcutaneously injected interferon beta-1a (Rebif®), for example, is more effective than intramuscularly administered interferon beta-1a.

The meta-analysis compared 44 randomized controlled trials (through 2010) involving a total of 17 401 MS patients. Of these, 9026 patients (23 studies) had RRMS, 7726 patients had secondary progressive MS (SPMS, 18 studies), and 579 patients had RRMS plus progression (3 studies). The median duration of treatment was 24 months.

According to this analysis, natalizumab was most effective in reducing the relapse rate (by 68%, odds ratio 0.32), with interferon beta-1a s.c. in second place at 55%. This was followed by glatiramer acetate (51%), interferon beta 1b and mitoxantrone (45% each and interferon beta 1a i.m. with 17% (n.s.). Significant differences (verum vs. placebo) were seen for delay in disability progression, with good evidence for natalizumab (odds ratio 0.56) and for interferon beta 1a s.c. (odds ratio 0.71).

In terms of reducing relapse activity, interferon beta-1a s.c. and natalizumab have the greatest efficacy with the highest level of evidence. The greatest benefit for delaying disability progression in patients with RRMS and SPMS has also been for these two drugs, with second-highest evidence. The odds ratio for natalizumab was 0.56 and for interferon beta 1a s.c. was 0.71. Regarding natalizumab, however, the risk of inducing progressive multifocal leukoencephalopathies – especially when used for more than 24 months – should be noted, according to the authors. Natalizumab is approved for escalation therapy, but not for the basic therapy of RRMS and SPMS. The differences between the compared MS therapeutics are clinically relevant and should be considered in future decisions on basic therapeutics. The Cochrane Collaboration was unable to make any statements on the efficacy and risk-benefit profile of the investigated substances for use over more than two years; long-term studies are therefore recommended.

Guideline-based dosing of interferon beta-1a s.c. is supported by data from the PRISMS-15 post-hoc analysis of long-term outcomes for patients with RRMS. After high-frequency use of the recommended dosage (44 μg three times weekly) for fifteen years, nine of ten patients remained ambulatory (EDSS score <6). Another study (IMPROVE) demonstrates a significant reduction in inflammation in the brain in RRMS as early as four weeks after starting therapy. Rebif® is thus the gold standard for the basic therapy of RRMS. Efficacy is of crucial importance, along with tolerability, adherence and good handling.

Source: Filippini G, Del Giovane C, et al: Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis. The Cochrane Collaboration 2013.

Publikation
  • InFo NEUROLOGIE & PSYCHIATRIE
Related Topics
  • analysis
  • benefit-risk ratio
  • beta-1a
  • Cochrane
  • Evidence
  • IMPROVE
  • Meta-analysis
  • MS
  • Multiple sclerosis
  • Risk
  • RRMS
  • SPMS
  • Thrust activity
Previous Article
  • Award

Thierry Carrel: best trainer in Europe

  • Cardiology
  • Congress Reports
  • News
  • Prevention and health care
  • RX
  • Surgery
View Post
Next Article
  • Apremilast

PDE4 inhibition in the treatment of inflammatory diseases.

  • Allergology and clinical immunology
  • Congress Reports
  • Dermatology and venereology
  • Rheumatology
  • RX
  • Studies
View Post
You May Also Like
View Post
  • 4 min
  • Case series

Bleeding prophylaxis for von Willebrand disease

    • Cases
    • Congress Reports
    • Gastroenterology and Hepatology
    • General Internal Medicine
    • Genetics
    • Hematology
    • RX
View Post
  • 4 min
  • A critical analysis of the evidence from 113 studies

Nutrition and depression

    • Education
    • Nutrition
    • Psychiatry and psychotherapy
    • RX
    • Studies
View Post
  • 5 min
  • An emerging interface with clinical relevance

Lung cancer and neuroscience

    • Education
    • Neurology
    • Oncology
    • Pneumology
    • RX
View Post
  • 5 min
  • Acute leukemia: Disease management

Priorities from the perspective of patients and family caregivers

    • Congress Reports
    • Hematology
    • Oncology
    • RX
    • Studies
View Post
  • 3 min
  • Bronchodilators for asthma

The early bird … gasps for air

    • Allergology and clinical immunology
    • Education
    • General Internal Medicine
    • Pharmacology and toxicology
    • Pneumology
    • RX
    • Studies
View Post
  • 9 min
  • Chronic kidney disease (CKD)

Triage of high-risk patients – Update 2025

    • Cardiology
    • Congress Reports
    • General Internal Medicine
    • Nephrology
    • RX
    • Studies
View Post
  • 3 min
  • AAD Annual Meeting: Review

HS and acne – what’s new?

    • Allergology and clinical immunology
    • Congress Reports
    • Dermatology and venereology
    • Infectiology
    • RX
    • Studies
View Post
  • 5 min
  • New perspectives for the optimization of cancer immunotherapy

Nanoparticle-mediated intratumoral gene editing of PD-L1 and galectin-9

    • Education
    • Oncology
    • RX
    • Studies
Top Partner Content
  • Herpes zoster

    Zum Thema
Top CME content
  • 1
    Yellow nail and Swyer-James syndrome
  • 2
    Individual therapy management for an optimized outcome – an update
  • 3
    Doing sport without fear or risk
  • 4
    UV protection and skin cancer screening – Update 2025
  • 5
    Rare malignancy from a dermatological perspective

Newsletter

Sign up and stay up to date

Subscribe
Medizinonline
  • Contact
  • General terms and conditions
  • Imprint

Input your search keywords and press Enter.